Marina Biotech's intranasal insulin delivery formulations for sale

A patent portfolio related to rapid-acting intranasal (IN) insulin delivery formulations, which is owned by USA-based Marina Biotech (Nasdaq: MRNA), nucleic acid-based drug discovery and development company, is available for licensing. The sale is being handled by ICAP Patent Brokerage.

Michael French, chief executive of Marina Biotech, commented: "Our intranasal insulin program, originally positioned to serve a diabetic patient population, holds additional promise in the potential treatment of CNS diseases such as Alzheimer's. Our proprietary formulation may provide distinct therapeutic advantages over other intranasal delivered insulin compounds. ICAP Patent Brokerage's platform provides an opportunity to quickly capitalize on the potential of this legacy program and ensures a timely and well-managed auction process for our intranasal compound portfolio."

Key attributes claimed for Marina Biotech's formulation are:
• US Investigational New Drug is active; preclinical studies, Phase I and multicenter Phase II clinical trials have been completed, allowing a rapid path to the market;
• Plasma insulin from intranasal administration crosses the blood brain barrier into the brain using the dedicated insulin transporter for potential effects on Alzheimer's and other CNS diseases;
• Very rapid PK profile: works more quickly on post-prandial glucose yet has a lower rate of post meal hypoglycemia compared with insulin analogs as well as a more rapid onset of action than a subcutaneously injected insulin analog;
• Delivers insulin to the nasal mucosa - does not enter the lungs;
• Well tolerated by patients;
• Can be formulated either with regular insulin or insulin analogs;
• Intranasal insulin formulated with regular insulin is stable at room temperature; and
• Published data is available